Given the critical role of MEK/ERK/AP-1 signaling in the positive regulation of DR4 expression as we recently demonstrated 29 and that osimertinib potently suppresses MEK/ERK signaling in EGFRm NSCLC cells 35, we speculated a potential effect of osimertinib on decreasing DR4 expression in EGFRm NSCLC cells. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.